YKL-06-061 is primarily investigated for its potential anti-inflammatory and neuroprotective properties. It has shown activity as a selective inhibitor of soluble epoxide hydrolase (sEH), an enzyme involved in the metabolism of epoxyeicosatrienoic acids (EETs), which are lipid mediators with protective effects in cardiovascular and nervous systems. By inhibiting sEH, YKL-06-061 helps maintain higher levels of EETs, leading to reduced inflammation, decreased neuropathic pain, and improved outcomes in models of stroke and neurodegenerative conditions. It is used in preclinical research to study pain modulation, brain injury, and inflammatory diseases, particularly where conventional therapies have limited efficacy. Its application is mainly confined to experimental models in neuroscience and pharmacology.